{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011350","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.258314+00:00","generated_at":"2026-05-31T11:36:56.541302+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Capricor Q2 2024: $11M loss, positive FDA pre-BLA meeting, DMD trial fully enrolled","bullets":["Net loss $11.0M ($0.35/sh) in Q2 2024 vs $7.4M ($0.29) in Q2 2023; revenue $4.0M.","Cash $29.5M at June 30, 2024 (down from $39.5M at Dec 31); raised $2.1M via ATM at $6.46/sh.","Positive pre-BLA meeting with FDA for deramiocel; HOPE-3 Phase 3 fully enrolled (105 subjects).","Top-line data from HOPE-3 Cohort A expected Q4 2024; 3-year HOPE-2 OLE showed +3.7 point PUL benefit.","Cash runway into Q1 2025; added to Russell 2000/3000 indexes."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011350","json":"https://secwatch.observer/filing/0001558370-24-011350.json","markdown":"https://secwatch.observer/filing/0001558370-24-011350.md","text":"https://secwatch.observer/filing/0001558370-24-011350.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024011350/0001558370-24-011350-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024011350/capr-20240807x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:36:56.541302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}